REal-World Analyses of Stroke - Thrombus Occlusion REtrieval

Status: Active_not_recruiting
Location: See all (37) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

To collect real-world evidence allowing assessment of functional, imaging, and safety outcomes of MicroVention market-released acute ischemic stroke devices when used at the direction of the treating physician.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Patient is ≥ 21 and ≤ 85 years of age.

• Patient has a pre-morbid mRS ≤ 1.

• Neuroimaging (CT/CTA and/or MR/MRA collected at no more than 90 minutes prior to groin puncture) demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation).

• Patient has an NIHSS score ≥ 5 at time of intervention.

• Symptom onset is within 8 hours of when groin puncture can be achieved.

• Patient will undergo treatment via femoral access and the decision to use femoral access has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.

• Patient will be treated using the direct aspiration as first line treatment technique and the decision to use this technique and the study device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.

• Patient or patient's legally authorized representative (LAR) has provided written informed consent.

• Patient is considered by the treating physician to be available for and able to complete all follow-up visits with a trained site investigator.

• Neuroimaging (CT/CTA and/or MR/MRA) demonstrates intracranial vessel occlusion.

• Symptom onset is within 24 hours of when arterial access puncture can be achieved.

• Patient will be treated using an FDA-cleared/approved and market-released MicroVention mechanical thrombectomy device as the initial, primary treatment device and the decision to use this device has been made by the treating physician outside the context of the RESTORE study and prior to study enrollment.

• Note: For the purposes of this protocol, ancillary/accessory devices such as balloon guide catheters and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.

• Patient or patient's legally authorized representative (LAR) has provided written informed consent within 48 hours of procedure.

Locations
United States
California
Pacific Neuroscience Institute (Providence)
Burbank
Mercy San Juan - Dignity Health Research Institute
Carmichael
Kaiser Permanente, Northern California
Redwood City
Colorado
UCHealth Memorial
Colorado Springs
Florida
Memorial Healthcare System
Hollywood
Tampa General Hospital
Tampa
Georgia
Augusta University
Augusta
Hawaii
The Queen's Medical Center
Honolulu
Illinois
Javon Bea Hospital
Rockford
Indiana
Goodman Campbell Brain and Spine
Carmel
Massachusetts
Brigham and Women's hospital
Boston
Baystate Medical Center
Springfield
Maryland
University of Maryland
Baltimore
Michigan
Ascension Borgess
Kalamazoo
Munson Medical Center
Traverse City
University of Michigan Health West
Wyoming
Minnesota
Allina Health (Abbott Northwestern Hospital)
Minneapolis
Missouri
SSM Health
Bridgeton
University of Missouri
Columbia
Washington University
Saint Louis
Nebraska
University of Nebraska Medical Center
Omaha
New Jersey
HMH Jersey Shore University Medical Center
Neptune City
New York
Montefiore
Bronx
Northshore University Hospital - Northwell
Manhasset
Mt. Sinai Health System
New York City
Stony Brook Medicine
Stony Brook
Ohio
University of Cincinnati
Cincinnati
Cleveland Clinic
Cleveland
ProMedica Toledo
Toledo
Oklahoma
University of Oklahoma Health Science Center
Oklahoma City
Pennsylvania
Geisinger
Danville
University of Pennsylvania Health Systems
Philadelphia
South Carolina
Prisma Health Upstate
Greenville
South Dakota
Sanford Medical Center
Sioux Falls
Tennessee
Semmes Murphy Clinic
Memphis
Virginia
INOVA
Falls Church
Washington
Swedish Health Services
Seattle
Time Frame
Start Date: 2020-07-15
Completion Date: 2025-09
Participants
Target number of participants: 1000
Treatments
Cohort I
Cohort I will focus on data collection on the SOFIA® Flow Plus 6F Aspiration Catheter used with the direct aspiration as first line treatment technique with the intent to evaluate per prespecified endpoints.
Cohort II
Cohort II will focus on data collection on MicroVention devices used for acute ischemic stroke treatment with the intent to evaluate standard outcomes while also generating additional research questions for analysis based on data collected.
Related Therapeutic Areas
Sponsors
Leads: Microvention-Terumo, Inc.

This content was sourced from clinicaltrials.gov